BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Extra | Dec 17, 2019
Clinical News

Axsome continues ascent with Phase III success in depression

With its depression therapy meeting in Phase III and plans to submit an NDA next year, Axsome has more than quadrupled its market cap since October, when it received a bump from a Phase II...
BC Extra | Dec 5, 2019
Financial News

Follow-on Roundup: Arrowhead, Kodiak, Relmada, Revance

Since market close on Tuesday, Arrowhead, Kodiak, Relmada and Revance raised a total of $718.5 million in follow-ons. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) raised $232 million after it priced an offering of 4 million shares at...
BioCentury | Oct 16, 2019
Product Development

Relmada data offer hope of safer option for depression

Relmada more than doubled its share price Tuesday after reporting Phase II data hinting that REL-1017 could be as effective at treating depression as J&J’s Spravato without the psychotomimetic side effects that require physician monitoring....
BC Extra | Jul 10, 2019
Clinical News

Michael Becker, patient advocate and biotech exec, dies at 50

Michael Becker, a former biotech entrepreneur and author who became a fierce patient advocate in his final years, passed away from metastatic HPV-related cancer. He was 50. Becker was president, CEO, CFO and director for...
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

Vaccination is widely considered one of the greatest medical achievements of modern civilization. Diseases that were commonplace less than a generation ago, such as polio, smallpox and diphtheria, are now increasingly rare because of vaccines....
BC Extra | Jun 3, 2015
Company News

Management tracks

Neurology play Pozen Inc. (NASDAQ:POZN) named Adrian Adams CEO, replacing retiring Chairman, President and CEO John Plachetka. Adams was CEO of Auxilium Pharmaceuticals Inc. , which Endo International plc (NASDAQ:ENDP; TSX:ENL) acquired. Cancer company Ziopharm Oncology...
Items per page:
1 - 10 of 35
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Extra | Dec 17, 2019
Clinical News

Axsome continues ascent with Phase III success in depression

With its depression therapy meeting in Phase III and plans to submit an NDA next year, Axsome has more than quadrupled its market cap since October, when it received a bump from a Phase II...
BC Extra | Dec 5, 2019
Financial News

Follow-on Roundup: Arrowhead, Kodiak, Relmada, Revance

Since market close on Tuesday, Arrowhead, Kodiak, Relmada and Revance raised a total of $718.5 million in follow-ons. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) raised $232 million after it priced an offering of 4 million shares at...
BioCentury | Oct 16, 2019
Product Development

Relmada data offer hope of safer option for depression

Relmada more than doubled its share price Tuesday after reporting Phase II data hinting that REL-1017 could be as effective at treating depression as J&J’s Spravato without the psychotomimetic side effects that require physician monitoring....
BC Extra | Jul 10, 2019
Clinical News

Michael Becker, patient advocate and biotech exec, dies at 50

Michael Becker, a former biotech entrepreneur and author who became a fierce patient advocate in his final years, passed away from metastatic HPV-related cancer. He was 50. Becker was president, CEO, CFO and director for...
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

Vaccination is widely considered one of the greatest medical achievements of modern civilization. Diseases that were commonplace less than a generation ago, such as polio, smallpox and diphtheria, are now increasingly rare because of vaccines....
BC Extra | Jun 3, 2015
Company News

Management tracks

Neurology play Pozen Inc. (NASDAQ:POZN) named Adrian Adams CEO, replacing retiring Chairman, President and CEO John Plachetka. Adams was CEO of Auxilium Pharmaceuticals Inc. , which Endo International plc (NASDAQ:ENDP; TSX:ENL) acquired. Cancer company Ziopharm Oncology...
Items per page:
1 - 10 of 35